胡旭波

2017-06-23

胡旭波是启明创投的主管合伙人。胡旭波共同领导了启明创投在生物医药行业内的投资,作为投资人参与了超过20个创业企业的成长,其中有一些已经成为上市公司或十亿美元市值公司。胡旭波代表启明执行的投资项目包括泰格医药(SZ: 300347)、BBI生命科学(HK: 01035)、透景生命科学股份、艾德生物股份、仁度生物、星童科技、飞依诺医疗、惠泰医疗、三友骨科、北海康成、Ark bio、生泰尔生物股份、瑞尔齿科、君和堂、微医移动医疗、梅斯医学等。

 2006年加入启明前,胡旭波曾经是IBM BCS的战略咨询顾问、以及若干家制药企业的市场营销管理。

 胡旭波拥有上海医科大学的医学士和ENPC MBA(上海校园)

William Hu is a managing partner of Qiming Venture Partners. William co-leads Qiming’s practice in healthcare sector and has been closely involved with more than 20 new ventures, some of which have become public or billion dollar market cap companies. On behalf of Qiming, he invested in Tigermed, Tellgen, AmoyDx, Rendu Bio, ET Healthcare, Vinno Medical, APT Medical, Sanyou Orthopedic, Canbridge, Ark Bio, Arrail Dental, JHT Clinics, WeDoctor, Medsci Clinical, and etc.

 Formerly, William served as a strategy consultant at IBM BCS, and Marketing & Sales management at several pharmaceutical companies.

 William holds Bachelor of Medicine from Shanghai Medical University and MBA from ENPC SH Campus.

上一篇:胡静珊
下一篇:苏楠
Powered by 飞色网络